1
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`September 3, 2024
`
`PGR2022-00025
`PGR2021-00088
`
`Neurocrine Biosciences, Inc. v. Spruce Biosciences, Inc.
`
`1
`
`Neurocrine 1051
`Neurocrine v. Spruce
`PGR2022-00025
`
`
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`September 3, 2024
`
`PGR2022-00025
`PGR2021-00088
`
`Neurocrine Biosciences, Inc. v. Spruce Biosciences, Inc.
`
`1
`
`Neurocrine 1051
`Neurocrine v. Spruce
`PGR2022-00025
`
`
`
`2
`
`
`
`
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`
`
`AONACIASLON-LIGIHX3SAILLVYLSNOWSG
`
`NOILONGOUYLNI4
`
`INTRODUCTION
`
`N
`
`2
`
`
`
`3
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`on May 18, 2021
`’908 patent; issued
`continuation of the
`’201 patent filed as
`Oct. 22, 2020
`
`issued on Dec. 1, 2020
`continuation of the PCT;
`’908 patent filed as a
`Apr. 18, 2019
`
`filed
`PCT/US2018/046760
`Aug. 14, 2018
`
`filed
`application 62/545,406
`Spruce’s provisional
`Aug. 14, 2017
`
`2020
`
`2019
`
`2018
`
`2017
`
`2016
`
`verucerfont (NBI-77860)
`including crinecerfont &
`antagonists to treat CAH,
`Discloses several CRF1 receptor
`(Ex. 1006)
`US2017/0020877
`Grigoriadis publishes
`Jan. 26, 2017
`
`CAH (Ex. 1008)
`antagonist, to treat
`CRF1 receptor
`study of verucerfont, a
`and published clinical
`Neurocrine completes
`Jan. 11, 2016
`
`Neurocrine’s Work Was Before Spruce’s Patents
`
`3
`
`
`
`4
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`pyrimidine
`(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)
`–3-4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-
`–“Compound 1”—tildacerfont
`receptor antagonist
`•Both patents disclose a single CRF1
`specification
`•Both patents share the same
`•PGR2022-00025: U.S. Patent 11,007,201
`•PGR2021-00088: U.S. Patent 10,849,908
`
`’201 patent, Ex. 1001
`’908 patent, Ex. 1001
`
`Spruce’s Patents
`
`4
`
`
`
`5
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR88 Pet. 17-23; Ex. 1002, 308-22, 328-29
`
`CRF1 receptor antagonist
`new claims replacing Compound 1 to a
`canceling all pending claims and adding
`submitted a preliminary amendment
`But when ’908 patent was filed, applicants
`
`sale or solvate thereof
`pharmaceutically acceptable
`Compound 1 (tildacerfont) or a
`limited to administration of
`Provisional and PCT claims were
`
`on May 18, 2021
`’908 patent; issued
`continuation of the
`’201 patent filed as
`Oct. 22, 2020
`
`issued on Dec. 1, 2020
`continuation of the PCT;
`’908 patent filed as a
`Apr. 18, 2019
`
`filed
`PCT/US/2018/046760
`Aug. 14, 2018
`
`filed
`application 62/545,40
`Spruce’s provisional
`Aug. 14, 2017
`
`2020
`
`2019
`
`2018
`
`2017
`
`2016
`
`verucerfont (NBI-77860)
`including crinecerfont &
`antagonists to treat CAH,
`Discloses several CRF1 receptor
`(Ex. 1006)
`US2017/0020877
`Grigoriadis publishes
`Jan. 26, 2017
`
`CAH (Ex. 1008)
`antagonist, to treat
`CRF1 receptor
`study of verucerfont, a
`and published clinical
`Neurocrine completes
`Jan. 11, 2016
`
`’908 and ’201 Patents Claim More Than Spruce Possessed
`
`5
`
`
`
`6
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR88, Ex. 1002, 328
`
`PGR88, Ex. 1003, 57
`
`Spruce Expanded Its Claims Beyond Its Written Description
`
`6
`
`
`
`7
`
`
`
`
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`
`
`AONACIASLON-LIGIHX3SAILLVYLSNOWSG
`
`ALIMA@VLNALVdNNAOSGNNOYD4
`
`GROUNDS OF UNPATENTABILITY
`
`M
`
`7
`
`
`
`8
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR88 Pet. 3-4
`
`Lack of enablement under 35 U.S.C. §112
`
`Lack of written description under 35 U.S.C. §112
`
`Grigoriadis in combination with Romano
`Obviousness under 35 U.S.C. §103 in view of
`
`1-25
`
`1-25
`
`Ground 5
`
`Ground 4
`
`5-6, 15-16
`
`Ground 3
`
`Grigoriadis and the knowledge of a skilled artisan
`Obviousness under 35 U.S.C. §103 in view of
`
`4, 10, 14, 20-22, 25
`
`Anticipation under 35 U.S.C. §102 by Grigoriadis
`
`1-4, 7-9, 11-14, 17-19, 21-24
`
`Basis for Rejection
`
`’908 Patent Claims
`
`Ground 2
`
`Ground 1
`
`Ground
`
`PGR2021-00088: Grounds of Unpatentability
`
`8
`
`
`
`9
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`Lack of written description under 35 U.S.C. §112
`the knowledge of the skilled artisan
`Grigoriadis and Turcu in combination with Romano and
`Obviousness under 35 U.S.C. §103 in view of
`artisan
`Grigoriadis and Turcu, and the knowledge of the skilled
`Obviousness under 35 U.S.C. §103 in view of
`knowledge of the skilled artisan
`Grigoriadis in combination with Romano and the
`Obviousness under 35 U.S.C. §103 in view of
`Grigoriadis and the knowledge of a skilled artisan
`Obviousness under 35 U.S.C. §103 in view of
`Anticipation under 35 U.S.C. §102 by Grigoriadis
`
`Basis for Rejection
`
`’201 Patent Claims
`
`PGR2022-00025: Grounds of Unpatentability
`
`PGR25 Pet. 4
`
`1-19
`
`Ground 6
`
`5-6
`
`Ground 5
`
`1-4, 7-19
`
`Ground 4
`
`5-6
`
`Ground 3
`
`10, 16-17, 19
`1-4, 7-9, 11-15, 18
`
`Ground 2
`Ground 1
`
`Ground
`
`9
`
`
`
`10
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR88 Pet. 60 (citing Ex. 1005 ¶ 34); PGR25 Pet. 26-27(citing Ex. 1005 ¶ 34)
`
`Spruce does not challenge this definition
`
`CAH or other adrenal disorders.
`conducting research concerning endocrine disorders, including
`ordinary skill would also have at least three years of experience
`employed to treat such disorders. The hypothetical person of
`and disorders, as well as knowledge of the treatment regimens
`endocrinology, and would have knowledge of hormone regulation
`would have a medical degree or a Ph.D. in a field related to
`•A hypothetical person of ordinary skill in the art of the ’908 patent
`
`A Person of Ordinary Skill in the Art
`
`10
`
`
`
`11
`
`
`
`
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`
`
`AONACIASLON-LIGIHX3SAILLVYLSNOWSG
`
`
`
`
`
`
`
`YO4NOILdIYDSAGNALLIYMALVNOAGV
`
`
`
`b4dad940SNNASDGAWIVIDAHL
`
`
`
`SLSINOSVLNVYOldsa90s4
`
`RECEPTOR ANTAGONISTS
`THE CLAIMED GENUS OF CRF1
`ADEQUATE WRITTEN DESCRIPTION FOR
`THE ’908 AND ’201 PATENTS LACK
`
`
`
`
`
`AIV1SLNALVdL0¢d.GNV806.SHL
`
`11
`
`
`
`12
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR88 Pet. 3-4 & Reply 4; PGR25 Pet. 4 & Reply 4
`
`Both PGRs may be decided on lack of written description
`
`because these grounds cover all challenged claims
`
`Lack of written description under 35 U.S.C. § 112
`
`Basis for Rejection
`
`’201 Patent Claims
`
`1-19
`
`Ground 6
`Ground
`
`Lack of written description under 35 U.S.C. § 112
`
`1-25
`
`Ground 4
`
`Basis for Rejection
`
`’908 Patent Claims
`
`Ground
`
`Grounds for Lack of Written Description
`
`12
`
`
`
`13
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR88 Pet. 70
`
`(Fed. Cir. 2010) (en banc)).
`2011) (quotingAriad Pharm., Inc. v. Eli Lilly & Co., 598 F.3d 1336, 1351
`Billups-Rothenberg, Inc. v. ARUP Labs., Inc., 642 F.3d 1031, 1036 (Fed. Cir.
`claimed.’”
`recognize that [the inventor] invented what is
`‘allow persons of ordinary skill in the art to
`inventor to disclose the claimed invention so as to
`“The written description requirement requires the
`
`Written Description Must Show Possession
`
`13
`
`
`
`14
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR88 Pet. 73, Ex. 1001, 1:28-55 & claim 1; PGR25 Pet. 76, Ex. 1001, 1:30-58 & claim 1
`
`•Both disclose only a single CRF1 receptor antagonist—
`•The ’908 and ’201 patents share the same specification
`
`Compound 1 (tildacerfont)
`
`•But the claims encompass a genus of CRF1 receptor
`
`antagonists
`
`Genus of CRF1 Receptor Antagonists
`The Patents Disclose Only One Species But Claim an Entire
`
`14
`
`
`
`15
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR25, Ex. 1001 (claim 1)
`PGR88, Ex. 1001 (claims 1 and 11);
`
`’201 patent—claim 1
`
`’908 patent—claims 1 and 11
`
`Their Functions
`The Genus of CRF1 Receptor Antagonists Are Claimed By
`
`15
`
`
`
`16
`
`PGR25 DI (Paper 20), 32
`PGR88 DI (Paper 21), 45;
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR25 DR Dec., 3
`PGR88 DR Dec., 12;
`
`CRF1 Receptor Antagonists
`The Director and Board Recognized That the Claims Cover a Genus of
`
`16
`
`
`
`17
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR88 DR Dec.,12
`
`Ariad Pharm., Inc. v. Eli Lilly & Co., 598 F.3d 1336, 1350 (Fed. Cir. 2010) (en banc)
`genus.”
`the art can ‘visualize or recognize’ the members of the
`to the members of the genusso that one of skill in
`scope of the genus, or structural features common
`representative number of speciesfalling within the
`the specification must disclose “either a
`To show sufficient description of the claimed genus,
`
`Written Description Legal Test For a Claimed Genus
`
`17
`
`
`
`18
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`the Claimed Functions
`Representative Number of Species that Achieve
`The ’908 and ’201 Patents Fail to Disclose a
`
`18
`
`
`
`19
`
`PGR25 DI (Paper 20), 32
`PGR88 DI (Paper 21), 45;
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR25 DR Dec., 3
`PGR88 DR Dec., 12;
`
`The Patents Disclose Only One Species—Compound 1
`
`19
`
`
`
`20
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`•Patents’ characterization of Compound 1 as “the Invention”
`
`limited to Compound 1
`is strong evidence that the scope of written description is
`
`•Gentry Gallery Inc. v. Berkline Corp., 134 F.3d 1473, 1478-80
`
`controls
`identified console as only possible location for
`invalid for lack of written description where disclosure
`
`•Claims that did not restrict the location of controls
`
`(Fed. Cir. 1998)
`
`PGR25 Pet. 75-76
`PGR88, Ex. 1001, code (57); PGR88 Pet. 71-72;
`
`Invention”
`The Patents Repeatedly Characterize Compound 1 as “The
`
`20
`
`
`
`21
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`38, 8:63-67, 9:19-22; 9:46-49
`PGR88, Ex. 1001, 1:30-55, 4:43-64, 8:35-
`PGR88 Pet. 12-14; PGR25 Pet. 12-14;
`
`Each Embodiment Refers to Compound 1
`
`21
`
`
`
`22
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR88 Pet. 14-15; PGR25 Pet. 14-15; PGR88, Ex. 1001, 36:32-41:49, 42:1-43:47; FIGS. 2 & 3
`
`***
`
`for Any Compound Other Than Compound 1
`The Specification Does Not Contain Any Description or Data
`
`22
`
`
`
`23
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR88 Pet. 14-15; PGR25 Pet. 14-15; PGR88, Ex. 1001, 44:7-47:58
`
`All Examples Are Limited to Compound 1
`
`23
`
`
`
`24
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR25 Reply 6
`PGR88 Reply 6-7;
`
`deposition transcript at
`
`30:22-31:22
`
`Ex. 1038
`
`One Species
`Spruce’s Expert Concedes the Patents Disclose Only
`
`24
`
`
`
`25
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR25 DI (Paper 20), 32
`PGR88 DI (Paper 21), 45;
`
`PGR25 DR Dec., 3
`PGR88 DR Dec., 13-14;
`
`Description Support for the Entire Claimed Genus
`Disclosure of One Species Does Not Provide Adequate Written
`
`25
`
`
`
`26
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR25 POPR (Paper 6), 42-45
`PGR88 POPR (Paper 8), 31-34
`
`Director Review Decision at 13:
`
`inherency
`(crinecerfont) cannot be relied on for
`conducted using a different species
`–Argued that the results of a trial study
`
`•POPR:
`
`Unpredictable
`Spruce Admits CRF1 Antagonist Receptor Activity Is
`
`26
`
`
`
`27
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR25 Pet. 23, 78-79
`PGR88 Pet. 21-22, 74-75
`
`Ex. 1002, 30-32
`
`Results For Compound 1
`During Prosecution, Spruce Relied on Allegedly Unexpected
`
`27
`
`
`
`28
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR88 Reply 9; PGR25 Reply 8
`
`deposition transcript at
`
`131:18-132:14
`
`Ex. 1038
`
`Had No Clinical Utility
`Spruce’s Expert Agrees Prior-Art CRF1 Receptor Antagonists
`
`28
`
`
`
`29
`
`PGR25 DI (Paper 20), 32
`PGR88 DI (Paper 21), 45;
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR25 DR Dec., 3
`PGR88 DR Dec., 13-14;
`
`the Art Is A Substitute for Disclosure (POR 64-66)
`The Board and Director Rejected Spruce’s Argument Knowledge in
`
`29
`
`
`
`30
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`Disclose a Structure-Function Relationship
`Neither the ’908 nor the ’201 Patent
`
`30
`
`
`
`
`
`
`
`
`
`
`
`AONACIASLON-LIGIHX3SAILLVYLSNOWSG
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`31
`
`Le
`
`
`
`wt
`
`'OAANUC
`
`ZQUOFASOePTTRAzoTpunoduos
`
`“soxy
`
`3SSHNLIMAHL
`
`IfQuoztesepT{TAstTpunoduoD
`
`
`
`'SAXWOAGNYOLLIVAC
`
`patents
`disclosed in the
`chemical structures
`There are no other
`
`
`
`94}UlPesojosip
`
`s}uajed
`
`6L-9-7E
`
`32:6-19
`
`oo
`
`Ex. 1001, 1:30-55, 4:43-64, 8:35-38, 8:63-67, 9:19-22; 9:46-49
`PGR88 Reply 5; PGR25 Reply 5;
`
`
`
`jejdugsueduojisodap
`
`deposition transcript at
`
`8E0L‘x7
`
`Ex. 1038
`
`
`
`
`
`
`
`
`
`
`
`aulAJUDBSOjOSiqs}jua}eYgJEU]SeeIBYWedxys,eonidse
`
`Structure of Compound 1
`Spruce’s Expert Agrees That Patents Disclose Only the
`
`
`
`JOEAN_ONAAS|YQYRACFsBjAesAT--&8,O70q3BOsNOA
`
`
`op“quejedg06,S843JOTMMODUIDd
`
`
`
`
`
`
`
`
`
`6b-9b-6:ZZ-61°6‘19-€9:98‘BE-GE'8‘b9-Eb-b‘GG-OE'L‘LOOL‘XZ
`
`|punodwodsjoeinjons
`SaiNjJONIjsJeDIW9Yd
`
`JO9U}JOOUdeBIOUL
`
`
`“gAidayGZYOd-GAiday889d
`
`31
`
`
`
`
`32
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR25 Reply 9-10; Ex. 1039, 8
`PGR88 Reply 10; Ex. 1041, 4667;
`
`Unique Features
`Spruce’s Own Publication Teaches Compound 1 Has Structurally
`
`32
`
`
`
`33
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR88 Reply 10; PGR25 Reply 9-10
`
`deposition transcript at
`
`52:19-53:13
`
`Ex. 1038
`
`Unique Features
`Spruce’s Expert Agrees That Compound 1 Has Structurally
`
`33
`
`
`
`34
`
`PGR25 DI (Paper 20), 32
`PGR88 DI (Paper 21), 45;
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR25 DR Dec., 3
`PGR88 DR Dec., 12-13;
`
`The Patents Do Not Disclose a Structure-Function Relationship
`
`34
`
`
`
`35
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR88 Reply 10; PGR25 Reply 9-10
`
`features.
`receptor can have widely diverse structural
`•The compounds that interact with the CRF1
`by a particular structure or structures.
`compounds that inhibit CRF1 receptors, not
`•CRF1 receptor antagonists are defined as
`
`PGR88, Ex. 1044
`
`¶¶ 89-92
`
`Dr. Cutler
`
`CRF1 Receptor Antagonists Are Structurally Diverse
`
`35
`
`
`
`36
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`Ex. 1029 Williams
`
`•Ex. 2014 ¶ 88
`relationship
`structure-function
`structure as teaching a
`Dr. Dobs points to this
`
`Williams Does Not Disclose a Structure-Function Relationship
`
`36
`
`
`
`37
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR88 Reply 10-11; Ex. 1044 ¶¶ 95-99
`
`Ex. 1029 Williams
`
`structural features as Figure 2
`same articlethat do not have the same
`•Reports other CRF1 antagonists in the
`OHP/A4)
`claimed results (reducing ACTH/17-
`the chemical structures achieve the
`•Says nothing about which features of
`•Does not even mention CAH
`
`Williams Does Not Disclose a Structure-Function Relationship
`
`37
`
`
`
`‘Lpaanbiy
`
`
`
`
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`
`
`AONACIASLON-LIGIHX3SAILLVYLSNOWSG
`
`
`
`OLAIdeYGZHDd“LLAION88HOd‘LL‘9%‘(r‘L)L“SBl4‘6ZOL“XZ
`
`8¢
`
`38
`
`
`
`“sysluoBeque'yy>pe2idAry
`
`
`
`
`
`
`
`Ex. 1029, Figs. 1 (1, 4), 2, 6, 11; PGR88 Reply 11; PGR25 Reply 10
`
`
`
`[Ayepayouerg|eee.
`
`oOoD
`
`
`
`
`
`"ysyslucBeque'y4y>yosuolBay"Zaunbiy
`
`
`
`
`
`Structurally Diverse
`Williams Teaches that CRF1 Receptor Antagonists are
`
`asJanigAyjeunjons
`
`
`
`
`
`
`
`asesjsiuobeluyJo}|de0ey14DJeu]SeUdDeS]SWIq
`
`
`
`38
`
`
`
`
`39
`
`PGR88 Reply 11; PGR25 Reply 10
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`Figure 2
`than the structure in
`different structures
`antagonists had
`other CRF1 receptor
`Dr. Dobs admitted that
`
`deposition transcript at
`
`130:13-131:16
`
`Ex. 1038
`
`Spruce’s Expert Admissions About Williams
`
`39
`
`
`
`40
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`•Ex. 2014 ¶ 88
`function relationship
`teaching a structure-
`Figure 1 of Fahmy as
`Dr. Dobs also points to
`
`Ex. 1018 Fahmy
`
`Fahmy Does Not Disclose a Structure-Function Relationship
`
`40
`
`
`
`41
`
`Ex. 1044 ¶¶ 100-02
`PGR88 Reply 11; PGR25 Reply 10-11;
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`structural features as Figure 1
`same articlethat do not have the same
`•Reports other CRF1 antagonists in the
`number of compounds
`•General structure encompasses a large
`OHP/A4)
`claimed results (reducing ACTH/17-
`the chemical structures achieve the
`•Says nothing about which features of
`
`Ex. 1018 Fahmy
`
`Fahmy Does Not Disclose a Structure-Function Relationship
`
`41
`
`
`
`42
`
`PGR88 Reply 11; PGR25 Reply 10-11
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`structure in Figure 1
`structures than the
`11 and 12 had different
`antagonists of Figures
`the CRF1 receptor
`Dr. Dobs admitted that
`
`deposition transcript at
`
`132:17-134:20
`
`Ex. 1038
`
`Spruce’s Expert Admissions About Fahmy
`
`42
`
`
`
`43
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`Description
`Spruce’s Arguments For Written
`
`43
`
`
`
`44
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR88 Reply 6-7; PGR25 Reply 5-7
`
`indications (e.g., ’908 patent at 11:57-64)
`–that CRF1 receptor antagonists have been studied for other
`53,10:54-65,11:48-12:26); or
`CRF in hormone regulation (e.g., ’908 patent at 1:14-17,10:47-
`–the differences between CRF receptor subtypes and the role of
`–the use of tildacerfont (e.g., ’908 patent at 12:27-31);
`
`•Spruce’s citations relate to:
`receptor antagonists can achieve the claimed functions
`•Nothing in the patents teaches whether the genus of CRF1
`
`The Patents Do Not Disclose “Class Effects”
`
`44
`
`
`
`45
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR88 Reply 8; PGR25 Reply 8
`
`1285, 1301 (Fed. Cir. 2014)
`–AbbVie Deutschland GmbH & Co., KG v. Janssen Biotech, Inc., 759 F.3d
`description
`•A trial-and-error approach does not show adequate written
`
`(Fed. Cir. 1997)
`–Regents of the Univ. of California v. Eli Lilly & Co., 119 F.3d 1559, 1567
`invention.”
`sufficient to satisfy the written description requirement of that
`•“[A] description which renders obvious a claimed invention is not
`oral dosing protocol) to identify effective compounds is irrelevant
`•Spruce’s argument that the patents identify a method (14-day
`
`Spruce Conflates Written Description with Obviousness
`
`45
`
`
`
`46
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR88 Sur-Reply 19; PGR25 Sur-Reply 18
`
`–Dr. Cutler’s Deposition, Ex. 2027, 73:3-12
`–Dr. Cutler’s Supplemental Declaration, Ex. 1044 ¶ 23
`
`•Sur-Reply 19, citing:
`depending on dosing
`wide therapeutic efficacy for “any CRF1 receptor antagonist”
`•Spruce argues Dr. Cutler testified to art-recognized class-
`
`Spruce Mischaracterizes Dr. Cutler’s Testimony
`
`46
`
`
`
`47
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR25, Ex. 1047 ¶ 23
`PGR88, Ex. 1044 ¶ 23
`Dr. Cutler Declaration,
`
`What Dr. Cutler’s Actually Said
`
`47
`
`
`
`48
`
`PGR88 Reply 11; PGR25 Reply 10-11
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`Spruce alleges
`efficacy for ‘any CRF1 receptor antagonist’ depending on dosing” as
`Dr. Cutler says nothing about any “art-recognized class-wide therapeutic
`
`deposition transcript at
`
`73:3-12
`
`Ex. 2027
`
`Dr. Cutler’s Deposition Testimony
`
`48
`
`
`
`49
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR88 Sur-Reply 24; PGR25 Sur-Reply 23
`
`Spruce’s Sur-Reply Arguments Ignore the Claims
`
`49
`
`
`
`50
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR88 Reply 4-5; PGR25 Reply 4-5
`
`Biotech, Inc., 759 F.3d 1285, 1301 (Fed. Cir. 2014)
`AbbVie Deutschland GmbH & Co., KG v. Janssen
`
`functionally claimed genus.
`genus or to predict what would be coveredby the
`correlation between structure and function for the whole
`are highly unpredictable, where it is difficult to establish a
`description support, especially in technology fields that
`vulnerable to invalidity challenge for lack of written
`Functionally defined genus claims can be inherently
`
`Spruce’s Claims Lack Adequate Written Description Support
`
`50
`
`
`
`51
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`Anticipation of the Challenged Claims
`
`51
`
`
`
`52
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR88 Pet. 3-4 & Reply 4; PGR25 Pet. 4 & Reply 4
`
`(Ex. 1006) under 35 U.S.C. §102
`Anticipation by disclosure of crinecerfont in Grigoriadis
`
`Basis for Rejection
`
`1-4, 7-9, 11-15, 18
`
`’201 Patent Claims
`
`Ground 1
`
`Ground
`
`in Grigoriadis (Ex. 1006) under 35 U.S.C. §102
`Anticipation by disclosure of crinecerfont and verucerfont
`
`Basis for Rejection
`
`1-4, 7-9, 11-14, 17-19, 21-24
`
`Ground 1
`
`’908 Patent Claims
`
`Ground
`
`Grounds for Anticipation: Grigoriadis’ Disclosure of Crinecerfont
`
`52
`
`
`
`53
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR88, Ground 1; PGR25, Grounds 1, 4
`
`(PGR88, Ex. 1037; PGR25, Ex. 1009)
`patent and ’201 patent challenged claims, as shown by Auchus
`
`1.Grigoriadis method re crinecerfontinherently anticipates ’908
`
`–Verucerfont (NBI-77860)
`–Crinecerfont
`receptor antagonists:
`•Grigoriadis discloses method of treating CAH using CRF1
`
`obvious, as shown by Grigoriadis & Turcu (PGR25, Ex. 1008)
`3.Grigoriadis method re verucerfontrenders ’201 patent claims
`
`claims, as shown by data in Grigoriadis (PGR88)
`
`2.Grigoriadis method re verucerfontanticipates ’908 patent
`
`Grigoriadis’ disclosure (Ex. 1006)
`
`53
`
`
`
` vsAONAGIAS
`
`
`LON-LIGIHXSSALLVYLSNOWSG
`
`
`
`
`
`jojdaaarYDal]“JUauIpoquiaJatjoue|[UsUy[eso]TWLeRcOO/LIOgSA"°NAM"!HONRIMIGNEwoNKoNddy1UdTeE
`
`
`JUOJJBONIO/,BYJUOLBDBULIDSIDELIOBUD@SOSOJOSIG
`
`
`
`
`
`
`
`
`pure‘(uladay..Jpunodwo-,,seo]pouayarosye)ourtue-/-urp
`
`
`“NG-N)UME“SGE9LE-dD“BLLTLSOO-Ad“6ZS98SASD
`
`
`-Jaotita“jWoptaorxed*T[E91€-dD“SLLOE-THNStIsttoseue
`
`-aydAuaul-¢-AXOTJSUU-p-OI0]Y9-zZ)-P|“{UOy
`
`
`“YSS ‘[aururepozenpi-z-([A-[|-uAdosd-z)-pj-;Aqiau-¢-[[Agia
`
`‘OLPLOSGI-INE=“IPOPE-IN‘“€£EZ-ONO=‘“FLEITI
`
`-TuLAd|e-¢*|JopozerAd|,Adoud(|A-¢-[ozerpexo-p‘z*[-,Aqaur
`
`
`
`~Ad([Ausyd[Auouen-9"p'Z)-/-[AMOLULN-9°¢*Z-[AU}O-N-[Al
`
`
`
`(jAueydAqyaur-p-oronp-¢)-[-[AdoudoypaAo-z-($[)|-N-(Auts
`
`-€)1-(SDIFN-[[Auoyd(Axo[Atnout)-p-|Atnowu-Z]-¢-]Ati9
`
`
`
`‘PO6dANCpue‘(outue-p-UIpreuLtAd|a-z*¢Jopor
`
`
`‘AINIDILNSBUIMOTTOTSt]SPYYSITEA‘sIpeUOBUS
`‘UsuIpoquiaueul[TSO]
`
`
`
`
`Grigoriadis Discloses Crinecerfont & Verucerfont
`
`¢‘LGbbb3e9001“xZ
`
`Ex. 1006 at ¶¶ 51, 54
`
`Grigoriadis,
`
`
`
`9001SNIEDOYNSNL
`
`sIetiostozsniod
`
`guec12er
`
`54
`
`
`
`
`
`(noretoe)orseTeWi
`
`L0UH
`
`
`
`Sayerspayruy
`
`54
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`JUOLIEONIE/
`
`Verucerfont
`
`
`
`JUOLOD9UUD
`
`Crinecerfont
`
`
`
`54
`
`
`
`
`
`
`55
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`’908 Patent, Ex. 1001
`
`’908 Patent Claims
`
`55
`
`
`
`56
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`’201 Patent, Ex. 1001
`
`’201 Patent Claims
`
`56
`
`
`
`57
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`Grigoriadis, Ex. 1006
`
`Neurocrine’s Prior Work Anticipates the Independent Claims
`
`57
`
`
`
`58
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR25 DI at 24
`
`PGR88 DI at 24-25
`
`Grigoriadis Discloses Administering a CRF1 Receptor Antagonist
`
`58
`
`
`
`59
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`Reductions
`Achieves the Claimed Hormone
`Administering Crinecerfont for CAH
`
`59
`
`
`
`60
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR25, Ex. 1009 at 6
`
`Auchus, PGR88, Ex. 1037 at 6
`
`Administering Crinecerfont Achieves the Claimed Reductions
`
`60
`
`
`
`61
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR25 Pet. 32-33
`PGR88 Pet. 46
`
`Hospira, Inc. v. Fresenius Kabi USA, LLC, 946 F.3d 1322, 1329 (Fed. Cir. 2020)
`itself prior art.”
`embodiment even if the extrinsic evidence is not
`what is ‘necessarily present’ in a prior art
`“Extrinsic evidence can be used to demonstrate
`
`Auchus Can be Used to Show Inherency
`
`61
`
`
`
`62
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR25, Ex. 1009 at 7
`
`Auchus, PGR88, Ex. 1037 at 7
`
`Administering Crinecerfont Achieves the Claimed Reductions
`
`62
`
`
`
`63
`
`PGR25, Ex. 1047 ¶ 35
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR88, Ex. 1044 ¶ 34
`
`PGR25, Ex. 1047 ¶ 35
`PGR88, Ex. 1044 ¶ 34
`Dr. Cutler Declaration,
`
`Administering Crinecerfont Achieves the Claimed Reductions
`
`63
`
`
`
`64
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR25, Ex. 1009 at 7,10
`
`Auchus, PGR88, Ex. 1037 at 7,10
`
`Administering Crinecerfont Achieves the Claimed Reductions
`
`64
`
`
`
`65
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR25, Ex. 1009 at 10
`
`Auchus, PGR88, Ex. 1037 at 10
`
`Crinecerfont Achieves the Claimed Reductions in Individual Patients
`
`65
`
`
`
`66
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR25, Ex. 1047 ¶ 36
`
`PGR88, Ex. 1044 ¶ 35
`
`PGR25, Ex. 1047 ¶ 36
`PGR88, Ex. 1044 ¶ 35
`Dr. Cutler Declaration,
`
`Crinecerfont Achieves the Claimed Reductions in Individual Patients
`
`66
`
`
`
`67
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PG88 DI at 26
`
`Administering Crinecerfont Achieves the Claimed Reductions
`
`67
`
`
`
`68
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PG25 DI at 26
`
`Administering Crinecerfont Achieves the Claimed Reductions
`
`68
`
`
`
`69
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR25 DR Dec., 3
`PGR88 DR Dec., 9-10;
`
`Administering Crinecerfont Achieves the Claimed Reductions
`
`69
`
`
`
`70
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR25, Ex. 1009 at 3, 5
`
`Auchus, PGR88, Ex. 1037 at 3, 5
`
`Auchus Demonstrates Claimed Reductions “From Baseline”
`
`70
`
`
`
`71
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`deposition transcript at
`Dr. Dobs, Ex. 1038
`
`81:18-82:20
`
`Auchus Demonstrates Claimed Reductions “From Baseline”
`
`71
`
`
`
`72
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR25, Ex. 1009 at 5
`
`Auchus, PGR88, Ex. 1037 at 5
`
`Auchus Demonstrates Reductions Maintained “Post 24 Hours”
`
`72
`
`
`
`73
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`Spruce’s Arguments For Anticipation
`
`73
`
`
`
`74
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR88 POR (Paper 29), 33-41
`
`Spruce: Auchus Does Not “Follow the Method of Grigoriadis”
`
`74
`
`
`
`75
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR88 DR Dec., 10
`
`Differences in Methods Are Not Recited in the Claims
`
`75
`
`
`
`76
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`deposition transcript at
`
`Dr. Dobs, Ex. 1038
`
`25:8-29:14
`
`Differences in Methods Are Not Recited in the Claims
`
`76
`
`
`
`77
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR25 POR, 41
`PGR88 POR, 42
`
`Spruce: Claims Require Reductions in AllHumans
`
`77
`
`
`
`78
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`201 Patent
`
`908 Patent
`
`Claims Require Reduction in “A Human” Not AllHumans
`
`78
`
`
`
`79
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR88, Ex. 1001, 3, 26
`
`Patent Data Shows Reduction in Some, Not All, Humans
`
`79
`
`
`
`80
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR 88, Ex. 1001, 43:53-65
`
`Patent Data Shows Reduction in Some, Not All, Humans
`
`80
`
`
`
`81
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`deposition transcript at
`Dr. Dobs, Ex. 1038
`
`20:8-22:2
`
`Patent Data Shows Reduction in Some, Not All, Humans
`
`81
`
`
`
`82
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`Ex. 1044 ¶ 38
`
`PGR88
`
`Claims Require Reduction in “A Human” Not AllHumans
`
`82
`
`
`
`83
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR88 Reply 16, 19; PGR25 Reply 15, 18
`
`In re Montgomery, 677 F.3d 1375, 1381, 1384 (Fed. Cir. 2012)
`
`prior art reference.”
`must have necessarily resulted from the practice of a
`“For anticipation by inherency, a later-claimed invention
`inevitably flows from the prior art disclosure….”
`out the claim steps.… [A] result is only inherent if it
`an efficacy requirement, efficacy is inherent in carrying
`“[W]e agree with the Board that even if the claim includes
`
`Limitations
`Administration of Crinecerfont Inherently Meets Claimed
`
`83
`
`
`
`84
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR88 POR, 46
`
`Spruce: Statistical Significance Required to Show Claimed Reductions
`
`84
`
`
`
`85
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR88, Ex. 1037, Fig.
`
`Ex. 1044 ¶¶ 44-45
`
`4
`
`Statistical Significance Not Required, but Shown by Auchus Results
`
`85
`
`
`
`86
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`Ex. 1047 ¶ 45
`
`PGR25
`
`Statistical Significance Not Required, but Shown by Auchus Results
`
`86
`
`
`
`87
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`Ex. 1044 ¶ 24
`
`PGR88
`
`Dr. Cutler: All Dose Cohorts Meet Claim Limitations
`
`87
`
`
`
`88
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR88
`
`Adopted Ex. 1036 ¶ 16
`
`Ex. 1005 ¶ 85
`
`•Spruce does not dispute anticipation of claims 3-4, 7-9, 11-14, 17-19,
`
`and 23 other than its arguments for the independent claims
`
`Grigoriadis’ Disclosure Anticipates the ’908 Patent Dependent Claims
`
`88
`
`
`
`89
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR88
`
`Adopted Ex. 1036 ¶ 16
`
`Ex. 1005 ¶ 92
`
`Grigoriadis’ Disclosure Anticipates the ’908 Patent Dependent Claims
`
`89
`
`
`
`90
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR88 DI, 35-37
`
`Grigoriadis’ Disclosure Anticipates the ’908 Patent Dependent Claims
`
`90
`
`
`
`91
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR88 Pet. 3-4 & Reply 4
`
`(Ex. 1006) under 35 U.S.C. §102
`Anticipation by disclosure of verucerfont in Grigoriadis
`
`Basis for Rejection
`
`1-4, 7-9, 11-14, 17-19, 21-24
`
`Ground 1
`
`’908 Patent Claims
`
`Ground
`
`Grounds for Anticipation: Grigoriadis’ Disclosure of Verucerfont
`
`91
`
`
`
`92
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`Grigoriadis, Ex. 1006, ¶¶ 90, 93
`
`Grigoriadis’ Disclosure of Verucerfont Anticipates the Claims
`
`92
`
`
`
`93
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`Grigoriadis, Ex. 1006, Fig. 5
`
`Grigoriadis’ Disclosure of Verucerfont Anticipates the Claims
`
`93
`
`
`
`94
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR88
`
`Adopted Ex. 1036 ¶ 16
`
`Ex. 1005 ¶ 65
`
`Grigoriadis’ Disclosure of Verucerfont Anticipates the Claims
`
`94
`
`
`
`95
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`Grigoriadis, Ex. 1006, Fig. 6
`
`Grigoriadis’ Disclosure of Verucerfont Anticipates the Claims
`
`95
`
`
`
`96
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR88
`
`Adopted Ex. 1036 ¶ 16
`
`Ex. 1005 ¶ 66
`
`Grigoriadis’ Disclosure of Verucerfont Anticipates the Claims
`
`96
`
`
`
`97
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR25 DI at 11
`
`PGR88 DI at 11
`
`Verucerfont ACTH, 17-OHP, A4 Reductions are “from baseline”
`
`97
`
`
`
`98
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`Grigoriadis, Ex. 1006, Fig. 4
`
`Placebo Administered Prior to Administration of the Drug (Verucerfont)
`
`98
`
`
`
`99
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`Ex. 1044 ¶ 67
`
`PGR88
`
`Grigoriadis’ Disclosure of Verucerfont Anticipates the Claims
`
`99
`
`
`
`100
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`deposition transcript at
`
`24:11-17
`
`Ex. 1038
`
`Spruce’s Expert Did Not Consider Board’s Construction
`
`100
`
`
`
`101
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`Ex. 1044 ¶ 69
`
`PGR88
`
`A Placebo Baseline is Appropriate
`
`101
`
`
`
`102
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`Ex. 1044 ¶ 70
`
`PGR88
`
`A Placebo Baseline is Appropriate
`
`102
`
`
`
`103
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR25 POR, 52-53
`
`Inter-Patient Variability Irrelevant to Anticipation in “A Human”
`
`103
`
`
`
`104
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`Obviousness of the Challenged Claims
`
`104
`
`
`
`105
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR25 Pet. 4 & Reply 4
`
`U.S.C. §103
`Grigoriadis (Ex. 1006) and Turcu(Ex. 1008) under 35
`Obvious in view of disclosure of verucerfont in
`
`1-4, 7-19
`
`Basis for Rejection
`
`’201 Patent Claims
`
`Ground 4
`
`Ground
`
`Verucerfont
`Grounds for Obviousness: Grigoriadis & Turcu Disclosure of
`
`105
`
`
`
`106
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`Turcu, Ex. 1008
`
`Grigoriadis, Ex. 1006
`
`Grigoriadis & Turcu Disclose Results of Same Study
`
`106
`
`
`
`107
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`Turcu, Ex. 1008, Table 3
`
`Administering Verucerfont Achieves A4 Reductions
`
`107
`
`
`
`108
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR25
`
`Adopted Ex. 1036 ¶ 16
`
`Ex. 1005 ¶ 58
`
`Administering Verucerfont Achieves A4 Reductions
`
`108
`
`
`
`109
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR25
`
`Adopted Ex. 1036 ¶ 16
`
`Ex. 1005 ¶ 61
`
`Obvious that A4 Reductions Would be Maintained with Repeat Dosing
`
`109
`
`
`
`110
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR88 Pet. 3-4 & Reply 4; PGR25 Pet. 4 & Reply 4;
`
`and Romano (Ex. 1007) under 35 U.S.C. §103
`Obvious in view of disclosures in Grigoriadis (Ex. 1006)
`and knowledge of a skilled artisan under 35 U.S.C. §103
`Obvious in view of disclosures in Grigoriadis (Ex. 1006)
`
`Basis for Rejection
`
`5-6
`
`Grounds 3, 5
`
`10, 16-17, 19
`
`’201 Patent Claims
`
`Ground 2
`
`Ground
`
`and Romano (Ex. 1007) under 35 U.S.C. §103
`Obvious in view of disclosures in Grigoriadis (Ex. 1006)
`and knowledge of a skilled artisan under 35 U.S.C. §103
`Obvious in view of disclosures in Grigoriadis (Ex. 1006)
`
`Basis for Rejection
`
`5-6, 15-16
`
`Ground 3
`
`4, 10, 14, 20-22, 25
`
`’908 Patent Claims
`
`Ground 2
`
`Ground
`
`Grounds for Obviousness: Dependent Claims
`
`110
`
`
`
`111
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR88 Pet. 58-59
`
`other than stated for Ground 1
`•Ground 3: Spruce does not dispute obviousness for reasons
`
`other than stated for Ground 1
`•Ground 2: Spruce does not dispute obviousness for reasons
`PGR88, ’908 Patent: Obviousness of Dependent Claims
`
`111
`
`
`
`112
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR25
`
`Adopted Ex. 1036 ¶ 16
`
`Ex. 1005 ¶¶ 87-88
`
`Obvious that A4 Reductions Would be Maintained Post 4 or 6 Weeks
`
`112
`
`
`
`113
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR25
`
`Adopted Ex. 1036 ¶ 16
`
`Ex. 1005 ¶¶ 87-88
`
`Obvious that A4 Reductions Would be Maintained Post 4 or 6 Weeks
`
`113
`
`
`
`114
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR25
`
`Adopted Ex. 1036 ¶ 16
`
`Ex. 1005 ¶¶ 91-95
`
`Grigoriadis’ Disclosure of Verucerfont Renders Claim 19 Obvious
`
`114
`
`
`
`115
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR25 Pet. 47, 65-66
`
`other than stated for Ground 4
`•Ground 5: Spruce does not dispute obviousness for reasons
`
`reasons other than stated for Ground 1
`•Grounds 3: Spruce does not dispute obviousness for
`PGR25, ’201 Patent: Obviousness of Dependent Claims
`
`115
`
`
`
`
`
`ObL
`
`116
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
` AONACIASLON-LIGIHX3SAILLVYLSNOWSG
`
`SIPUBSJUT[aSegWOT9,()]ISA]JeAqpaonpelstUBUUNY&UT
`
`“wingax}otAuLaysturpeBursrduroHV)
`
`
`
`IUL[AAT]ALLOWPresUae“]WEDJOpoyaUraL],“TZ
`
`
`[2A2edHO-/[PlesUlatayaa“TTWIE[SJopoyeuatl],‘77
`
`jodasar‘yDeBJOyoueaanoapgqe-ATpeoynaderey)&
`
`AljeannaseueydeJoystoseweJodasal|yD&JowNoWweveundetoodow“Bay&O]
`
`
`
`SIpueoulaseq
`
`‘JomayesajgeydacaeAyjeanneseuueydeIoIsmioneyTe
`
`
`
`Ul[aaa(ATOV)euouoyordoqoonrosouerpeueUTeTaTpAs
`
`
`-AU-/[8Ula‘PooJay]pesayqeydasoe
`
`
`UBUINYat)ULpaanpalstaaal(qHO-L[)euolaisesoidAxorp
`
`
`
`pisejdiodAy[euarpe[eyuasu0sFZuryeayVor
`
`UlBISE]!b[BWesUOSSuleayfopopeW“TT
`
`SULa\stunupeSursuduos
`
`a()[JsealJeAqpoonparstuewNYayy
`
`“OUTfaseqWOT%O]\seayWeAgINOge
`
`
`
`
`
`UONONIJSUOT)WIe|D)@
`
`
`
`7H806'6FS'01SAFONWaIET(OvWy$9j¥IGpou<!
`
`0707°190ruseJoapeq(sb)‘Je90013MOH
`
`
`JUua}ed806.“LOOL‘XZ
`
`Claim Construction
`
`
`
`Ex. 1001, ’908 Patent
`
`rieMEK
`
`szsnreWIO¥“1
`
`116
`
`zag06
`
`i010
`
`116
`
`
`
`
`
`117
`
`DEMONSTRATIVE EXHIBIT -NOT EVIDENCE
`
`PGR88 Pet. 23-28, DI at 11; PGR25 Pet. 27-30, DI at 11
`
`release of ACTH
`“Administered 4 hours prior to sleeping”(’908 patent claim 24): administered 4 hours prior to the circadian
`
`“Maintained at a reduced level post 6
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
